Edition:
United Kingdom

Genomic Health Inc (GHDX.OQ)

GHDX.OQ on NASDAQ Stock Exchange Global Select Market

54.79USD
17 Aug 2018
Change (% chg)

-- (--)
Prev Close
$54.79
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
93,863
52-wk High
$59.48
52-wk Low
$26.54

Select another date:

Wed, May 2 2018

BRIEF-Genomic Health Q1 Loss Per Share $0.11

* GENOMIC HEALTH ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND REPORTS RECENT BUSINESS PROGRESS

BRIEF-Tailorx Results Aid In Assessing The Effect Of Chemotherapy In Women With Early-Stage Breast Cancer And Oncotype Dx Breast Recurrence Score Results Of 11 To 25

* LANDMARK TAILORX RESULTS AID IN ASSESSING THE EFFECT OF CHEMOTHERAPY IN WOMEN WITH EARLY-STAGE BREAST CANCER AND ONCOTYPE DX BREAST RECURRENCE SCORE® RESULTS OF 11 TO 25

BRIEF-Genomic Health Reports Q4 Earnings Per Share $0.05

* GENOMIC HEALTH ANNOUNCES 2017 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS, PROVIDES 2018 FINANCIAL OUTLOOK

BRIEF-Genomic Health Reports Q4 Earnings Per Share $0.05

* GENOMIC HEALTH ANNOUNCES 2017 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS, PROVIDES 2018 FINANCIAL OUTLOOK

BRIEF-Genomic Health Expands Offering To Prostate Cancer Patients With Launch Of Oncotype DX AR-V7 Nucleus Detect Test To Predict Treatment Response In Metastatic Disease

* GENOMIC HEALTH EXPANDS OFFERING TO PROSTATE CANCER PATIENTS WITH LAUNCH OF ONCOTYPE DX® AR-V7 NUCLEUS DETECT™ TEST TO PREDICT TREATMENT RESPONSE IN METASTATIC DISEASE Source text for Eikon: Further company coverage:

Select another date: